A Noncoding Variant Near PPP1R3B Promotes Liver Glycogen Storage and MetS, but Protects Against Myocardial Infarction

Abstract Context Glycogen storage diseases are rare. Increased glycogen in the liver results in increased attenuation. Objective Investigate the association and function of a noncoding region associated with liver attenuation but not histologic nonalcoholic fatty liver disease. Design Genetics of Ob...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 2021-02, Vol.106 (2), p.372-387
Hauptverfasser: Kahali, Bratati, Chen, Yue, Feitosa, Mary F, Bielak, Lawrence F, O’Connell, Jeffrey R, Musani, Solomon K, Hegde, Yash, Chen, Yanhua, Stetson, L C, Guo, Xiuqing, Fu, Yi-ping, Smith, Albert Vernon, Ryan, Kathleen A, Eiriksdottir, Gudny, Cohain, Ariella T, Allison, Matthew, Bakshi, Andrew, Bowden, Donald W, Budoff, Matthew J, Carr, J Jeffrey, Carskadon, Shannon, Chen, Yii-Der I, Correa, Adolfo, Crudup, Breland F, Du, Xiaomeng, Harris, Tamara B, Yang, Jian, Kardia, Sharon L R, Launer, Lenore J, Liu, Jiankang, Mosley, Thomas H, Norris, Jill M, Terry, James G, Palanisamy, Nallasivam, Schadt, Eric E, O’Donnell, Christopher J, Yerges-Armstrong, Laura M, Rotter, Jerome I, Wagenknecht, Lynne E, Handelman, Samuel K, Gudnason, Vilmundur, Province, Michael A, Peyser, Patricia A, Halligan, Brian, Palmer, Nicholette D, Speliotes, Elizabeth K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Context Glycogen storage diseases are rare. Increased glycogen in the liver results in increased attenuation. Objective Investigate the association and function of a noncoding region associated with liver attenuation but not histologic nonalcoholic fatty liver disease. Design Genetics of Obesity-associated Liver Disease Consortium. Setting Population-based. Main Outcome Computed tomography measured liver attenuation. Results Carriers of rs4841132-A (frequency 2%-19%) do not show increased hepatic steatosis; they have increased liver attenuation indicative of increased glycogen deposition. rs4841132 falls in a noncoding RNA LOC157273 ~190 kb upstream of PPP1R3B. We demonstrate that rs4841132-A increases PPP1R3B through a cis genetic effect. Using CRISPR/Cas9 we engineered a 105-bp deletion including rs4841132-A in human hepatocarcinoma cells that increases PPP1R3B, decreases LOC157273, and increases glycogen perfectly mirroring the human disease. Overexpression of PPP1R3B or knockdown of LOC157273 increased glycogen but did not result in decreased LOC157273 or increased PPP1R3B, respectively, suggesting that the effects may not all occur via affecting RNA levels. Based on electronic health record (EHR) data, rs4841132-A associates with all components of the metabolic syndrome (MetS). However, rs4841132-A associated with decreased low-density lipoprotein (LDL) cholesterol and risk for myocardial infarction (MI). A metabolic signature for rs4841132-A includes increased glycine, lactate, triglycerides, and decreased acetoacetate and beta-hydroxybutyrate. Conclusions These results show that rs4841132-A promotes a hepatic glycogen storage disease by increasing PPP1R3B and decreasing LOC157273. rs4841132-A promotes glycogen accumulation and development of MetS but lowers LDL cholesterol and risk for MI. These results suggest that elevated hepatic glycogen is one cause of MetS that does not invariably promote MI.
ISSN:0021-972X
1945-7197
DOI:10.1210/clinem/dgaa855